LMDX.F Share Price Performance
US$0.01
0.01 (4,900.00%)
Price US$0.01
Share PriceUS$0.01
LMDX.F Community Narratives
There are no narratives available yet.
Recent LMDX.F News & Updates
No updates
LumiraDx Limited Key Details
Last Reported Earnings
Jun 30, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.94
- Gross Margin
- -3.73%
- Net Profit Margin
- -267.19%
- Debt/Equity Ratio
- -201.0%
LumiraDx Limited Competitors
About LMDX.F
- Founded
- n/a
- Employees
- 1210
- CEO
- WebsiteView website
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.
U.K. Market Performance
- 7 Days: -2.6%
- 3 Months: 18.0%
- 1 Year: 16.0%
- Year to Date: 12.3%
Over the last 7 days, the market has dropped 2.6%, driven by declines in the Energy and Materials sectors of 4.0% and 4.2%, respectively. In contrast to the last week, the market is actually up 16% over the past year. Earnings are forecast to grow by 13% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading